Developers of the most energy-efficient, lowest-cost CO2 separation & capture system.



Problem they are Solving?

The need for less expensive and less electricity-intensive carbon capture and sequestration (CCS) technologies.

Their Solution?

A patented enzyme immobilization and stabilization polymer technology that potentially cuts the cost of CCS by more than half and puts the resulting captured carbon to work in a variety of potential uses.

Chrysalix take from Portfolio Manager, Mike Walkinshaw


1. What is the insight that led to Chrysalix investing?

The intersection of biology with energy markets is showing great promise. The ability to encapsulate an enzyme and allow it to retain its function outside of its host is a unique and valuable capability. We see the Akermin technology enabling economic large scale separation and capture of CO2 for sequestration.


2. What is the company’s biggest strength?

The scientific team is highly entrepreneurial and innovative and continues to enable the cross-over of biological science into new functional areas. Their IP position is strong and they have developed key industry relationships over the past few years.


3. What is the implication of this company being successful?

Global warming is the defining issue of our times. The ability to capture CO2 from a coal power plant flue gas stream at a very low cost will be fundamental to the continuance of our current lifestyles.


Gallery Image Gallery Image
Previous   Next



Akermin interview with
the Global CCS Institute.



“Chrysalix has helped us make a lot of contacts and helped to open doors for us. They have jumped in and really understood our issues, and given us great advice and counsel. They do the things a good investor should be doing.”

Barry Blackwell – President & CEO, Akermin

Bottom Bitty